Biomerica’s complete screening test portfolio authorized in Egypt

Biomerica (BMRA) announced today that the Egyptian Drug Authority has granted authorization for Biomerica’s complete portfolio of rapid tests for conditions associated with cancers and chronic diseases across Egypt. This authorization allows Biomerica’s screening products to be marketed and distributed throughout Egypt, supporting early identification of conditions associated with colorectal, breast, and prostate cancers, as well as chronic diseases including kidney disease and Helicobacter pylori infection. All tests are designed for point-of-care use enabling deployment across diverse clinical and community settings, including regions with limited infrastructure.